Glycopeptide antibiotics are an important class of antibiotics that inhibit bacterial cell wall biosynthesis. However, emergence of antibacterial resistance has posed a major threat towards this class of antibiotics. of A major aspect of our work involves undertaking synthetic modifications of such block-buster antibiotics such as vancomycin against which resistance has started to evolve, with the aim of restoring their activity, either by countering the resistance element, or by conferring additional mechanism of action. We have achieved notable progress in development of semisynthetic glycopeptide antibiotics which have successfully tackled vancomycin resistance. We are also working on semi-synthetic modifications of antibiotics of other classes, such as meropenem (beta-lactam) etc.
